Chairman of Aclarion Releases 2026 Shareholder Letter

Aclarion, Inc., a healthcare technology company, recently released its 2026 Shareholder Letter from the Chairman, highlighting key clinical, financial, and operational priorities. The company is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to assist physicians in pinpointing the source of chronic low back pain. Aclarion is on track to deliver an initial internal readout of its 300-patient CLARITY trial by the end of Q3, with early interim results expected to be publicly disclosed in Q4 of 2026.

Executive Chairman of Aclarion, Jeff Thramann, emphasized the company’s favorable financial position heading into 2026. Recent financings have extended Aclarion’s cash runway into 2028, eliminating the need for additional capital raises. The company’s balanced capital structure and clean balance sheet have allowed it to terminate its At-The-Market (ATM) offering in early 2025, with its ELOC expiring on December 31, 2025. With 2,882,371 shares outstanding on a fully diluted basis, Aclarion is committed to ensuring that the value generated by its early data directly benefits existing shareholders.

Aclarion is part of a new wave of software-native MedTech innovators, delivering its solutions entirely through the cloud. This approach offers software-level gross margins, scalability, and continuous algorithmic advancements without the constraints of manufacturing or inventory management. In 2026, the company plans to implement a structured investor-awareness strategy, focusing on engaging institutional healthcare investors, enhancing physician-led clinical education, and increasing visibility in financial and medical media.

Aclarion’s Nociscan is a SaaS platform that utilizes Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. By analyzing MRS data from an MRI machine, Nociscan provides physicians with insights into distinguishing between painful and nonpainful discs in the lumbar spine, aiding in treatment decision-making for patients with chronic low back pain. The company’s innovative technology aims to revolutionize the diagnostic process for this prevalent condition.

Looking ahead, Aclarion envisions significant milestones in its CLARITY trial and is committed to advancing technologies that enhance patient care. The company’s dedication to shareholder alignment, financial stability, and technological innovation positions it for continued success in the healthcare technology sector. Investors and stakeholders can access the full 2026 Shareholder Letter on the company’s website for detailed information on Aclarion’s strategic direction and operational updates.